X 1. In house marketing and distribution: Kirkov X 2. Generic OxyContin- FIRST TO FILE Sept 25, 2023- $720 Million —3. Generic Concerta- $1.2 BILLION —4. Generic Vyvanse- $5.1 BILLION —5. Vigabatrin —6. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million —7.Patented Unique ADF (w/o naltrexone)-- NDA —8. Mikah monster —9. Undisclosed —10.:Antimetabolite ANDA- Methotrexate -$600 Million —11. Undisclosed Antimetabolite ANDA- $42 Million —12. Full ownership of Adderall XR —13. Prasco/Burel Adderall agreement —14. Dexcel partnership approval by Israeli health for European distribution
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.